StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research note released on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Several other research firms have also issued reports on TENX. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.
Read Our Latest Research Report on TENX
Tenax Therapeutics Trading Up 0.8 %
Institutional Trading of Tenax Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth $1,026,000. Vestal Point Capital LP bought a new stake in shares of Tenax Therapeutics during the third quarter worth $288,000. Stonepine Capital Management LLC bought a new stake in shares of Tenax Therapeutics during the third quarter worth $173,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics during the third quarter worth $101,000. Finally, Millennium Management LLC bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth $166,000. Institutional investors own 1.67% of the company’s stock.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Tenax Therapeutics
- What does consumer price index measure?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is the Euro STOXX 50 Index?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- 10 Best Airline Stocks to Buy
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.